📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Raymond Lifestyle Appoints HUL Veteran Kalpana Singh as Chief Marketing Officer
Raymond Lifestyle Limited has appointed Ms. Kalpana Singh as its Chief Marketing Officer, effective March 05, 2026. Ms. Singh is a seasoned professional with 20 years of experience in brand building and consumer insights, including an 18-year tenure at Hindustan Unilever Limited (HUL). Her previous roles include Marketing Director at HUL and regional leadership positions across the Middle East, Turkey, and North Africa. This appointment is expected to bolster the company's strategic marketing and brand positioning efforts in the lifestyle sector.
Key Highlights
Ms. Kalpana Singh appointed as Chief Marketing Officer (CMO) effective March 05, 2026
Brings 20 years of distinguished experience in brand building and category strategy
Spent 18 years at Hindustan Unilever Limited (HUL) in various senior leadership roles
Previously served as Marketing Director at HUL and Business Group Director for international regions
Will report directly to the Chief Executive Officer (CEO) as part of the Senior Management Personnel
💼 Action for Investors
Investors should view this as a positive move to strengthen the leadership team with top-tier FMCG talent. Monitor the impact of new marketing initiatives on brand growth and market share over the next few quarters.
IMP Powers Seeks Shareholder Approval for Material Related Party Transactions for FY 2026-27
IMP Powers Limited has initiated a postal ballot process to obtain shareholder approval for material related party transactions (RPTs) planned for the financial year 2026-27. The proposed transactions involve GSEC Limited and Electrify Energy Private Limited, a promoter group entity. Voting is conducted through a remote e-voting facility open from February 27, 2026, to March 28, 2026. The company maintains that these transactions will be conducted in the ordinary course of business and at arm's length.
Key Highlights
Proposed material RPTs with GSEC Limited for the financial year 2026-27.
Proposed material RPTs with Electrify Energy Private Limited (Promoter Company) for FY 2026-27.
Remote e-voting period scheduled from February 27, 2026, to March 28, 2026.
Eligibility for voting determined by the cut-off date of February 20, 2026.
Results of the postal ballot to be declared within two working days of the voting closure.
💼 Action for Investors
Investors should examine the specific transaction limits and nature of business with these related parties to ensure no conflict of interest. Monitor the voting outcome to be announced by March 30, 2026.
Mukand Ltd Seeks Approval for Re-appointment of CMD and Material Related Party Transactions
Mukand Limited has issued a postal ballot notice seeking shareholder approval for the re-appointment of Shri Niraj Bajaj as Chairman and Managing Director for a 3-year term starting July 5, 2026. The company is also proposing the re-appointment of Shri Nirav Bajaj as Whole-Time Director for 3 years effective May 16, 2026. Additionally, resolutions are being presented for material related party transactions for FY 2026-27 involving the company and its subsidiary, Mukand Heavy Engineering Limited. The e-voting period for these resolutions runs from February 20 to March 21, 2026.
Key Highlights
Proposed re-appointment of Shri Niraj Bajaj as CMD for 3 years starting July 5, 2026
Proposed re-appointment of Shri Nirav Bajaj as Whole-Time Director for 3 years starting May 16, 2026
Approval sought for material related party transactions for FY 2026-27
Remote e-voting period scheduled from February 20, 2026, to March 21, 2026
Results of the postal ballot to be declared on or before March 24, 2026
💼 Action for Investors
Investors should review the proposed remuneration and the nature of the material related party transactions to ensure they align with corporate governance standards. Eligible shareholders should participate in the e-voting process before the March 21 deadline.
Windlas Biotech Seeks Approval for Director Re-appointments and ₹1.56 Cr Annual Remuneration
Windlas Biotech has initiated a postal ballot to seek shareholder approval for the re-appointment of Mr. Ashok Kumar Windlass as Whole-time Director for a five-year term starting May 3, 2026. The proposal includes a fixed annual remuneration of ₹1.56 crore and requires a special resolution as he is over 75 years of age. Additionally, the company is seeking a second five-year term for Independent Directors Mr. Vivek Dhariwal and Mr. Gaurav Gulati. Shareholders can participate in remote e-voting from February 18 to March 19, 2026.
Key Highlights
Proposed re-appointment of Mr. Ashok Kumar Windlass as WTD for 5 years with ₹1.56 crore annual salary.
Special resolution required for Mr. Windlass to continue in office beyond the age of 75 years.
Re-appointment of two Independent Directors, Vivek Dhariwal and Gaurav Gulati, for second 5-year terms.
Remote e-voting period set for February 18, 2026, to March 19, 2026, with a cut-off date of February 13.
Aggregate remuneration of promoter executive directors may exceed SEBI Regulation 17(6)(e) limits but will remain within Section 197 ceilings.
💼 Action for Investors
Investors should monitor the voting results to ensure leadership continuity and evaluate if the proposed remuneration aligns with the company's performance. No immediate portfolio changes are necessary based on this routine governance update.
IMP Powers Reports Q3 Net Loss of ₹2.17 Crore; Auditors Issue Qualified Opinion
IMP Powers Limited reported a standalone net loss of ₹217.10 lakhs for the quarter ended December 31, 2025, a significant increase from the ₹108.86 lakhs loss in the prior year's quarter. Revenue from operations remains extremely low at just ₹12.76 lakhs for the quarter, though up slightly from ₹8.14 lakhs year-on-year. The statutory auditors have issued a qualified opinion, highlighting concerns over unconfirmed trade receivables, lack of impairment testing on assets, and improper inventory valuation. For the nine-month period, the company's total loss has reached ₹630.78 lakhs, indicating deep financial distress.
Key Highlights
Net loss for Q3 FY26 widened to ₹217.10 lakhs from ₹108.86 lakhs in Q3 FY25.
Revenue from operations remains negligible at ₹12.76 lakhs for the quarter.
Auditors issued a qualified opinion citing failure to perform impairment testing despite significant operational reductions.
Inventory is currently understated as the company failed to include direct labor and manufacturing overheads in its valuation.
Trade receivables, other financial assets, and bank balances are subject to pending confirmations and reconciliations.
💼 Action for Investors
Investors should exercise extreme caution as the company faces severe financial instability, negligible revenues, and multiple auditor qualifications regarding its financial reporting. The lack of impairment testing and inventory discrepancies suggest significant risks to the carrying value of assets.
IMP Powers Reports Q3 Net Loss of ₹217 Lakhs; Auditor Issues Qualified Opinion
IMP Powers Limited reported a net loss of ₹217.10 Lakhs for the quarter ended December 31, 2025, widening from a loss of ₹108.64 Lakhs in the previous year's corresponding quarter. Total income for the quarter stood at ₹163.50 Lakhs, a decline from ₹181.60 Lakhs year-on-year. The statutory auditors have issued a qualified opinion, highlighting that the company failed to perform impairment testing despite significant operational reductions and ongoing losses. Furthermore, the company resumed manufacturing but failed to include direct labor and overheads in inventory valuation, leading to understated inventory figures.
Key Highlights
Net loss widened to ₹217.10 Lakhs in Q3 FY26 compared to ₹108.64 Lakhs in Q3 FY25.
Total income for the quarter decreased to ₹163.50 Lakhs from ₹181.60 Lakhs year-on-year.
Auditors issued a qualified opinion citing lack of impairment testing on assets despite indicators of potential impairment.
Inventory valuation for the quarter excluded direct labor and manufacturing overheads, resulting in understated inventory and potentially overstated expenses.
Trade receivables, other financial assets, and bank balances are subject to pending confirmations and reconciliations.
💼 Action for Investors
Investors should exercise extreme caution as the company continues to report losses and faces significant auditor qualifications regarding asset valuation and financial reconciliations. The lack of impairment testing and inventory valuation issues suggest that the reported financial position may not accurately reflect the underlying asset quality.
Neuland Labs Q3FY26 Revenue Up 11.4% to ₹447.8 Cr; EBITDA Margin Dips to 19%
Neuland Laboratories reported an 11.4% YoY increase in total income to INR 447.8 crores for Q3FY26, with the CMS (CDMO) segment contributing over 50% of revenue. EBITDA margins compressed to 19% from previous highs, primarily due to a shift in product mix and a one-time INR 10 crore impact from labor codes. Despite a significant 9-month capex of INR 254 crores, the company maintains a strong net cash position of INR 202.6 crores. Management noted that the absence of a specific high-margin CMS product shipment and delays in Paliperidone contributed to the quarterly margin dip.
Key Highlights
Total income grew 11.4% YoY to INR 447.8 crores, driven by commercial CMS projects.
EBITDA margin stood at 19%; adjusted for a INR 10 crore labor code impact, the margin would be 21%.
9-month gross margin remains healthy at 56% compared to 55% in the previous year.
Significant 9-month capex of INR 254 crores funded largely through internal accruals and customer advances.
Working capital cycle stretched to 145 days due to higher inventories and uneven delivery flows.
💼 Action for Investors
Investors should look past the quarterly margin volatility and focus on the successful ramp-up of expanded CMS capacity in Unit 3. The company's transition toward complex molecules and peptides remains the primary long-term value driver.
Mukand Ltd Q3 Net Profit Rises to ₹17.21 Cr; Re-appoints Niraj Bajaj as CMD
Mukand Limited reported a consolidated net profit of ₹17.21 crore for the quarter ended December 31, 2025, a slight increase from ₹16.31 crore in the year-ago period. Revenue from operations grew to ₹1,300.18 crore, up from ₹1,222.67 crore year-on-year. A significant highlight is the ongoing sale of 17.77 acres of land in Thane for approximately ₹673 crore, for which the company has already received a ₹110 crore advance. The board also ensured leadership continuity by re-appointing Niraj Bajaj as Chairman and Managing Director for a three-year term starting July 2026.
Key Highlights
Revenue from operations increased to ₹1,300.18 crore in Q3 FY26 from ₹1,222.67 crore in Q3 FY25.
Net profit for the quarter stood at ₹17.21 crore, showing steady growth from ₹15.90 crore in the previous quarter.
Agreement executed for land sale worth ₹673 crore in Thane, with ₹110 crore advance already received.
Niraj Bajaj re-appointed as CMD and Nirav Bajaj as Whole-Time Director for 3-year terms starting in 2026.
Slump sale of the Industrial Machinery Division to subsidiary MHEL is expected to be completed shortly.
💼 Action for Investors
Investors should focus on the successful closure of the ₹673 crore land sale as it will significantly improve the company's liquidity and debt profile. The steady earnings and management continuity suggest a stable outlook, making it a 'Watch' for further deleveraging milestones.
Mukand Ltd Q3 PAT Rises to ₹17.21 Cr; Board Approves ₹673 Cr Land Sale and CMD Re-appointment
Mukand Limited reported a steady performance for Q3 FY26 with a standalone net profit of ₹17.21 crore, up from ₹16.31 crore in the same quarter last year. Revenue from operations saw a modest growth of 6.3% YoY, reaching ₹1,300.18 crore. A significant highlight is the ongoing sale of 17.77 acres of land in Thane for ₹673 crore, which is expected to provide a substantial liquidity boost. The board also ensured leadership continuity by re-appointing Niraj Bajaj as Chairman and Managing Director for a three-year term starting July 2026.
Key Highlights
Standalone Revenue from Operations grew to ₹1,300.18 crore in Q3 FY26 compared to ₹1,222.67 crore in Q3 FY25.
Net Profit for the quarter stood at ₹17.21 crore, including a loss of ₹4.14 crore from discontinuing operations.
Executed agreement for sale of land parcels in Thane for approximately ₹673 crore, with ₹110 crore advance already received.
Re-appointed Niraj Bajaj as CMD and Nirav Bajaj as Whole-Time Director for 3-year terms starting in 2026.
Proceeding with the slump sale of the Industrial Machinery Division to a wholly-owned subsidiary to streamline business structure.
💼 Action for Investors
Investors should view the ₹673 crore land sale as a major positive catalyst for debt reduction and balance sheet strengthening. While operational growth is modest, leadership stability and asset monetization plans make this a stock to watch for value unlocking.
Mukand Ltd Q3 PAT at ₹17.21 Cr; Land Sale for ₹673 Cr and CMD Re-appointment Approved
Mukand Limited reported a Profit After Tax (PAT) of ₹17.21 crore for Q3 FY26, a slight increase from ₹16.31 crore in the previous year's corresponding quarter. Revenue from operations rose to ₹1,300.18 crore, reflecting stable demand. A major highlight is the ongoing sale of land parcels for ₹673 crore, which is expected to provide a substantial liquidity boost upon completion. The board also ensured management continuity by re-appointing Niraj Bajaj as Chairman and Managing Director for another three years.
Key Highlights
Q3 FY26 Revenue from operations increased to ₹1,300.18 crore from ₹1,222.67 crore YoY.
Net Profit for the quarter reached ₹17.21 crore, up from ₹16.31 crore in Q3 FY25.
Progressing on a ₹673 crore land sale in Thane; ₹110 crore advance already received.
Industrial Machinery Division being transferred to a subsidiary via slump sale for better focus.
Niraj Bajaj re-appointed as CMD for a 3-year term effective July 2026.
💼 Action for Investors
Investors should monitor the realization of the remaining ₹563 crore from the land sale as it could significantly strengthen the balance sheet. The steady operational performance and leadership continuity provide a positive outlook for long-term holders.
Nandan Denim Q3 FY26 Net Profit Falls 55% YoY to ₹2.97 Cr; Revenue Down 46%
Nandan Denim reported a sharp decline in its financial performance for the quarter ended December 31, 2025, with revenue from operations dropping 46% YoY to ₹499.53 crore. Net profit for the quarter fell to ₹2.97 crore from ₹6.58 crore in the previous year's corresponding quarter. On a sequential basis, revenue also saw a significant contraction from ₹784.69 crore in Q2 FY26. Furthermore, the company is currently contesting penalties levied by BSE and NSE regarding non-compliance with SEBI Regulation 17(1A).
Key Highlights
Revenue from operations declined 46% YoY to ₹499.53 crore from ₹926.15 crore.
Net Profit decreased by 54.8% YoY to ₹2.97 crore compared to ₹6.58 crore in Q3 FY25.
Total expenses were significantly lower at ₹496.87 crore versus ₹919.37 crore YoY, driven by reduced material costs.
Earnings Per Share (EPS) for the quarter stood at ₹0.02, down from ₹0.05 YoY.
The company has applied for a waiver of penalties from stock exchanges regarding Board composition non-compliance.
💼 Action for Investors
Investors should exercise caution as the company shows a significant contraction in scale and profitability. Monitor the resolution of the regulatory penalty and look for signs of margin stabilization in upcoming quarters.
Windlas Biotech Q3 Revenue Up 20% to INR 233 Cr; Plant 6 Completion Set for FY26
Windlas Biotech reported a strong Q3 FY26 with revenue growing 20% YoY to INR 233 crores, marking its 12th consecutive quarter of record revenue. The CDMO vertical led the performance with 23% growth, while the Exports segment surged 36% due to increased penetration in semi-regulated markets. Management confirmed that Plant 6 is on track for mechanical completion by the end of FY26, which will bring the total revenue capacity to approximately INR 1,100 crores. For the first 9 months of FY26, the company achieved an EPS of INR 24.02, representing a 12% YoY increase.
Key Highlights
Q3 FY26 revenue grew 20% YoY to INR 233 Cr, while 9M FY26 revenue rose 19% to INR 666 Cr.
9M FY26 EBITDA (excluding ESOP expenses) stood at INR 89 Cr with a margin of 13.3%.
Exports vertical grew 36% in Q3 FY26, significantly outperforming domestic volume growth trends.
Plant 6 mechanical completion expected by end of FY26 with an estimated capex of INR 50-60 Cr.
Total revenue capacity target set at INR 1,000 Cr for oral solids and INR 100 Cr for injectables.
💼 Action for Investors
Investors should focus on the successful commissioning and utilization of Plant 6 and the injectable facility as primary growth catalysts. The company's consistent 12-quarter revenue growth streak and expansion in high-margin exports make it a strong candidate for long-term portfolios in the CDMO space.
Windlas Biotech Faces Suspension of Codeine Syrup Production; ₹55.21 Cr Revenue Impact
Windlas Biotech has received a Show Cause Notice from the Food Safety & Drug Administration (Uttarakhand), resulting in the temporary suspension of Codeine-containing cough syrup manufacturing. This specific product line contributed ₹55.21 crore to the company's total revenue in the current financial year as of February 9, 2026. While the suspension is limited to this product category, the company is preparing a detailed response to address the regulatory concerns and resume operations. Investors should monitor the duration of this suspension as it affects a material revenue stream.
Key Highlights
Temporary suspension of Codeine-containing cough syrup manufacturing by Uttarakhand authorities.
Affected product line contributed ₹55.21 crore to revenue in the current FY up to Feb 9, 2026.
Suspension is limited to Codeine-based products; other manufacturing operations remain unaffected.
Company is in the process of filing a detailed response to the Show Cause Notice within stipulated timelines.
💼 Action for Investors
Investors should monitor the duration of the suspension as the affected revenue is significant. Watch for the company's formal response and any further regulatory actions or clearances from the Food Safety & Drug Administration.
Neuland Labs Q3FY26 Results: PAT Drops 60.2% YoY to Rs 40.4 Cr as Margins Contract
Neuland Laboratories reported a challenging Q3FY26 with a significant 60.2% YoY decline in Profit After Tax (PAT) to Rs 40.4 crore. While Total Income grew 11.4% YoY to Rs 447.8 crore, it fell 13.2% on a sequential basis. The company faced severe margin pressure, with EBITDA margins contracting to 19.0% from 30.4% in the previous quarter, driven by an unfavorable product mix and higher operating expenses. Management remains focused on long-term investments despite the current subdued profitability.
Key Highlights
Total Income for Q3FY26 reached Rs 447.8 crore, up 11.4% YoY but down 13.2% QoQ.
EBITDA fell 5.9% YoY and 45.8% QoQ to Rs 85.0 crore.
EBITDA margins contracted sharply to 19.0%, down from 22.5% YoY and 30.4% QoQ.
Profit After Tax (PAT) plummeted 60.2% YoY to Rs 40.4 crore compared to Rs 101.4 crore in Q3FY25.
Management cited product mix shifts and increased operating expenses as primary reasons for subdued margins.
💼 Action for Investors
Investors should exercise caution due to the sharp sequential decline in margins and profitability. It is essential to monitor management's guidance on the recovery of the product mix and the impact of ongoing investments on future earnings.
Neuland Labs Q3FY26: Revenue Grows 11% YoY, but PAT Declines 60% on Margin Pressure
Neuland Laboratories reported a mixed Q3FY26 with total income rising 11.4% YoY to ₹447.8 crore, supported by growth in the CMS and Prime segments. However, EBITDA margins contracted significantly by 350 bps to 19.0% due to an unfavorable product mix and higher operating expenses. Consequently, PAT for the quarter fell 60% YoY to ₹31.5 crore. Despite the bottom-line pressure, the company remains net debt-free with a cash surplus of ₹202.6 crore and continues to invest in R&D expansion.
Key Highlights
Total Income for Q3FY26 stood at ₹447.8 crore, up 11.4% YoY, while 9MFY26 income reached ₹1,264.4 crore.
EBITDA margin compressed to 19.0% in Q3FY26 from 22.5% in the previous year's quarter.
PAT for Q3FY26 dropped 60% YoY to ₹31.5 crore, with 9MFY26 PAT down 35% at ₹150.6 crore.
CMS segment remains robust with 98 active projects, including 19 commercial molecules and 10 in Phase-3.
Capital expenditure for 9MFY26 reached ₹254 crore, including plans for a new 140k sq. ft. R&D facility at Genome Valley.
💼 Action for Investors
Investors should be cautious regarding the sharp margin contraction and PAT decline, which may lead to short-term stock price volatility. Focus on the management's ability to improve the product mix and the long-term growth potential of the expanding CMS project pipeline.
Neuland Labs Q3 FY26 PAT Drops 60% YoY to ₹40.4 Cr; EBITDA Margins Contract to 19%
Neuland Laboratories reported a mixed Q3 FY26 with total income growing 11.4% YoY to ₹447.8 crore, but profitability faced significant pressure. EBITDA fell 5.9% YoY to ₹85 crore, with margins contracting sharply to 19.0% from 22.5% a year ago due to an unfavorable product mix and higher operating expenses. Net profit saw a steep decline of 60.2% YoY to ₹40.4 crore, though the previous year's base was higher due to exceptional items. Management remains optimistic about long-term growth driven by the NCE drug substance segment and niche capabilities despite the short-term margin volatility.
Key Highlights
Total Income grew 11.4% YoY to ₹447.8 crore but declined 13.2% on a sequential (QoQ) basis.
EBITDA margins contracted by 350 bps YoY and 1,140 bps QoQ to 19.0%.
Profit After Tax (PAT) plummeted 60.2% YoY to ₹40.4 crore from ₹101.4 crore in the previous year.
Management cited unfavorable product mix and increased operating expenses as primary reasons for margin compression.
9MFY26 Total Income reached ₹1,264.5 crore with cumulative EBITDA at ₹284 crore.
💼 Action for Investors
Investors should exercise caution due to the significant sequential margin compression and monitor the management's commentary on the sustainability of the current product mix. The stock may face short-term pressure until there is clarity on the recovery of EBITDA margins back toward the 25-30% range seen in previous quarters.
Neuland Labs Q3 PAT Drops 60% YoY to ₹40.57 Cr; Revenue Up 10.5% YoY
Neuland Laboratories reported a consolidated revenue of ₹439.71 crore for Q3 FY26, a 10.5% increase compared to ₹398.03 crore in the same quarter last year. However, Profit After Tax (PAT) saw a sharp decline of 60% YoY to ₹40.57 crore, down from ₹101.59 crore, partly due to a high base effect from an exceptional gain in the previous year. On a sequential basis, revenue fell 14.5% and PAT dropped 58% from Q2 FY26. Rising finance costs and manufacturing expenses further pressured margins during the quarter.
Key Highlights
Consolidated Revenue from Operations grew 10.5% YoY to ₹439.71 crore but declined 14.5% QoQ.
Net Profit (PAT) plummeted 60% YoY to ₹40.57 crore, impacted by higher operational costs and a lack of exceptional gains seen in the prior year.
Finance costs spiked to ₹6.79 crore compared to ₹2.22 crore in Q3 FY25, reflecting higher interest or debt obligations.
9M FY26 PAT stands at ₹151.33 crore, a 34.8% decrease from ₹232.30 crore in 9M FY25.
Geographically, USA and North America revenue grew to ₹191.80 crore, while India revenue saw a sharp decline to ₹91.59 crore from ₹172.07 crore in the previous quarter.
💼 Action for Investors
Investors should exercise caution as the company faces significant margin pressure and a sharp sequential slowdown in revenue. Monitor management's commentary regarding the spike in finance costs and the volatility in the India segment revenue.
Windlas Biotech Re-appoints Founder and Two Independent Directors for 5-Year Terms
Windlas Biotech has approved the re-appointment of its founder, Mr. Ashok Kumar Windlass, as Whole-time Director for a five-year term starting May 2026. The board also re-appointed Chairman Mr. Vivek Dhariwal and Mr. Gaurav Gulati as Independent Directors for their second five-year terms. These moves ensure leadership continuity and maintain a board with deep expertise in pharmaceutical manufacturing and business strategy. The re-appointments are subject to shareholder approval and will extend the current leadership's tenure until 2031.
Key Highlights
Mr. Ashok Kumar Windlass re-appointed as Whole-time Director for a 5-year term from May 3, 2026, to May 2, 2031.
Chairman Vivek Dhariwal re-appointed as Independent Director for a second 5-year term starting May 6, 2026.
Gaurav Gulati re-appointed as Independent Director for a second 5-year term starting May 6, 2026.
The leadership team brings combined experience from major firms like Pfizer, Baxter, and Oyo Hotels.
💼 Action for Investors
Investors should view this as a sign of management stability and continuity, which is beneficial for long-term strategic execution. No immediate action is required as the existing leadership remains in place.
Windlas Biotech Q3FY26: Revenue up 20% to Rs 233 Cr; 12th Consecutive Record Revenue Quarter
Windlas Biotech reported a strong 20% YoY revenue growth in Q3FY26, reaching Rs 233.1 crore, marking its 12th consecutive quarter of record revenue. While reported PAT for the quarter saw a marginal decline of 4% to Rs 14.9 crore due to non-cash ESOP expenses, adjusted PAT grew significantly. The core CDMO vertical, contributing over 70% of revenue, grew by 23% YoY, while the export segment surged by 36%. For the 9-month period, the company maintained healthy momentum with a 19% revenue increase and a 13% rise in reported PAT.
Key Highlights
Revenue from operations grew 20% YoY to Rs 233.1 crore in Q3FY26, driven by the CDMO segment.
Adjusted EBITDA (excluding ESOP expenses) for 9MFY26 rose 26% YoY to Rs 89 crore with a 13.3% margin.
CDMO revenue increased 23% YoY in Q3FY26, contributing 71.6% to the total revenue mix.
Export vertical showed significant traction with 36% YoY growth in Q3FY26, reaching Rs 13.2 crore.
Plant-6 is on track for mechanical completion by the end of FY26, signaling future capacity expansion.
💼 Action for Investors
Investors should focus on the strong 20% top-line growth and the robust performance of the CDMO segment, looking past the reported PAT dip caused by non-cash ESOP expenses. The consistent revenue records and upcoming capacity at Plant-6 suggest a positive long-term growth trajectory for the company.
Windlas Biotech Q3FY26 Revenue up 20% to ₹233 Cr; Adjusted PAT Surges 38% YoY
Windlas Biotech reported its 12th consecutive quarter of record revenue, reaching ₹233 crore in Q3FY26, a 20% YoY increase. While reported PAT for Q3 fell 4% to ₹15 crore due to significant non-cash ESOP charges, the adjusted PAT (excluding ESOPs) surged 38% to ₹22 crore. The core CDMO vertical, contributing 73% of revenue, grew 23% in Q3, while the Exports segment jumped 36%. The company remains net debt-free with ₹213 crore in liquidity and expects to complete its Plant-6 expansion by the end of FY26.
Key Highlights
9MFY26 Revenue grew 19% YoY to ₹666 Cr, driven by strong performance across CDMO and Export verticals.
Adjusted EBITDA (excluding non-cash ESOP expenses) for 9MFY26 rose 26% YoY to ₹89 Cr with a 13.3% margin.
CDMO vertical revenue grew 23% YoY in Q3FY26 to ₹167 Cr, with 67% of the portfolio focused on complex generics.
Exports segment showed robust momentum with 36% YoY growth in Q3FY26, increasing penetration in RoW markets.
Maintains a strong financial position with ₹213 Cr liquidity and remains net debt-free.
💼 Action for Investors
Investors should focus on the adjusted (Ex-ESOP) profit figures to assess operational performance, as non-cash accounting charges are temporarily masking strong bottom-line growth. The consistent revenue trajectory and shift toward complex generics and exports make this a positive long-term growth story.